Cargando…
Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175943/ https://www.ncbi.nlm.nih.gov/pubmed/37187779 http://dx.doi.org/10.1002/trc2.12388 |
_version_ | 1785040325345017856 |
---|---|
author | Van Dyck, Christopher H. O'Dell, Ryan S. Mecca, Adam P. |
author_facet | Van Dyck, Christopher H. O'Dell, Ryan S. Mecca, Adam P. |
author_sort | Van Dyck, Christopher H. |
collection | PubMed |
description | |
format | Online Article Text |
id | pubmed-10175943 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101759432023-05-13 Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials Van Dyck, Christopher H. O'Dell, Ryan S. Mecca, Adam P. Alzheimers Dement (N Y) Letter John Wiley and Sons Inc. 2023-05-11 /pmc/articles/PMC10175943/ /pubmed/37187779 http://dx.doi.org/10.1002/trc2.12388 Text en © 2023 The Authors. Alzheimer's & Dementia: Translational Research & Clinical Interventions published by Wiley Periodicals LLC on behalf of Alzheimer's Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Letter Van Dyck, Christopher H. O'Dell, Ryan S. Mecca, Adam P. Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials |
title | Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials |
title_full | Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials |
title_fullStr | Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials |
title_full_unstemmed | Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials |
title_short | Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials |
title_sort | disease severity and minimal clinically important differences in clinical outcome assessments for alzheimer's disease clinical trials |
topic | Letter |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175943/ https://www.ncbi.nlm.nih.gov/pubmed/37187779 http://dx.doi.org/10.1002/trc2.12388 |
work_keys_str_mv | AT vandyckchristopherh diseaseseverityandminimalclinicallyimportantdifferencesinclinicaloutcomeassessmentsforalzheimersdiseaseclinicaltrials AT odellryans diseaseseverityandminimalclinicallyimportantdifferencesinclinicaloutcomeassessmentsforalzheimersdiseaseclinicaltrials AT meccaadamp diseaseseverityandminimalclinicallyimportantdifferencesinclinicaloutcomeassessmentsforalzheimersdiseaseclinicaltrials |